An observational study of adverse drug reactions in hospitalized patients of drug resistance tuberculosis taking PMDT therapy in a tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20213363Keywords:
Adverse drug reaction, PMDT, Second line antitubercular drugsAbstract
Background: Drug resistant tuberculosis is an important public health issue in India. The treatment regimen followed is Programmatic Management of Drug resistant Tuberculosis (PMDT) approach. Adverse drug reactions (ADRs) are a serious issue which increases the risk of defaulter rate if poorly managed. Thus study was undertaken to assess the ADRs caused by PMDT therapy in indoor patients of Department of Respiratory Medicine in a tertiary care hospital at Surat.
Methods: The prospective and observational study was carried out for one year period. The causality was determined by World Health Organization (WHO) Uppasala Monitoring Centre (UMC) scale and severity was determined by Modified Hartwig and Siegel scale. Fisher exact test was applied for statistical analysis.
Results: Among 24 drug resistant tuberculosis patients, 12 (50%) patients developed ADRs due to second line antitubercular drugs. Occurrence of ADRs was more among Category V (100%) as compared to Category IV (36.8%). Occurrence of ADRs was more among females (60%). The commonly involved systems are auditory system (33.3%). Majority of ADRs developed within 61-90 days (66.7%) of initiation of drug therapy. Highest percentage of ADRs causing drugs was pyrazinamide (27.8%). On evaluation of the causality of ADRs, majority were found to be possible (53.3%). The severity assessment showed that most of the patients ADRs were of moderate level (73.3%).
Conclusions: PMDT therapy is complicated but early management and reporting of ADRs decreases default rate.
Metrics
References
Global Tuberculosis Control. Epidemiology, Strategy, Financing. World Health Organization. 2009. www.afro.who.int/index.php?option=com_docman&task=doc_download. Accessed on 10th June, 2021.
Anti-tuberculosis Drug Resistance in the World. World Health Organization. Report No. 4 (2008). www.who.int/tb/publications/2008/drs_report4_26feb08.pdf. Accessed on 10th June, 2021.
Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. The Ind J of Med Res. 2011;133(5):529.
Iseman MD, Goble M. Multidrug-resistant tuberculosis. N Engl J Med. 1996;334:267.
Pablos-Mendez A, Raviglione M C, Laszlo A. Global surveillance for antituberculosis-drug resistance. World Health Organization–International Union Against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med. 2003;338:1641-9.
Anti-tuberculosis drug resistance in the world. Fourth global report. World Health Organization. Geneva: 2008. www.who.int/tb/publications/2008/drs_repo rt426feb08.pdf . Accessed on 10th June, 2021.
Sotgiu G, Ferrara G, Matteelli A. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33:871-81.
Migliori GB, Loddenkemper R, Blasi F. 125 years after Robert Koch’s discovery of the tubercle bacillus: the new XDR-TB threat. Is ‘‘science’’ enough to tackle the epidemic? Eur Respir J. 2007;29:423-7.
Revised National Tuberculosis Control Programme (Modules 5-9), Directorate General of Health Services, Ministry of Health and Family Welfare, India. 2011. Available at: https://tbcindia.gov.in/ WriteReadData/l892s/8320929355Guidelines%20for%20PMDT%20in%20India%20-%20May%202 012.pdf. Accessed on 3 June 2021.
Central TB Division (CTD), Directorate General of Health services, Ministry of Health and Family Welfare, Government of India (2012) Programmatic Management of Drug Resistant TB (PMDT) Guidelines. CTD, New Delhi.
Prasad R, Singh A, Srivastava R, Hosmane GB, Kushwaha RAS, Jain. Frequency of Adverse Events Observed with Second-Line Drugs among Patients Treated for Multidrug-Resistant Tuberculosis. Indian Journal of Tuberculosis. 2016;63:106-14.
Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, Zhan S. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. American Journal of Therapeutics. 2013;23:e521-30.
Ganiyu A, Avong Y, Akinyede A, Ige O, tayeb O, Taleatu F, Omayeka A, Babawale V, Oreagba I. Prevalence of Adverse Drug Reactions to Second Line Anti Tuberculosis Drugs in Nigeria: A Cross-Sectional Study. Journal of Tuberculosis Research 2021;9(2):90-102.
Baig M, Kale M, Lamb A. A prospective observational pharmacovigilance study of adverse drug reaction monitoring in patients of MDR-TB at tertiary care hospital. Int J Basic Clin Pharmacol. 2018;7(7):1291-6.
Kumari A, Sharma P, Kansal D, Bansal R, Negi R. Adverse Drug Reactions in Patients on Second Line Anti-Tubercular Drugs for Drug Resistant Tuberculosis in Rural Tertiary Care Hospital in North India. Journal of Tuberculosis Research. 2018;6(3):207-14.
Maharjan S, Singh A, Khadka D, Aryal M. Drug Resistance Pattern in Pulmonary Tuberculosis Patients and Risk Factors Associated with Multi-Drug Resistant Tuberculosis. Journal of Tuberculosis Research. 2017;5:106-17.
Prasad R. Management of multi-drug resistant tuberculosis Practitioner’s view point. Indian Journal of Tuberculosis. 2007;54:3-11.
Downloads
Published
How to Cite
Issue
Section
